NCT06298019View on ClinicalTrials.gov

Study of KYV-101 Anti-CD19 CAR T Therapy in Adult Dermatomyositis

PHASE1RecruitingINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

August 2, 2024

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2039

Conditions
Dermatomyositis
Interventions
BIOLOGICAL

KYV-101

The investigational product, KYV-101, is an autologous CD19-targeted CAR T-cell immunotherapy.

Trial Locations (2)

94305

RECRUITING

Stanford University, Stanford

94304-5755

RECRUITING

Stanford University, Palo Alto

All Listed Sponsors
lead

Stanford University

OTHER